Sign in

Private company

Freeline Therapeutics Holdings plc

Freeline Therapeutics Holdings plc is a British biological products company based in Stevenage, no longer active.2

Last updated Oct 21, 2026.

Overview

-$89.0MNet income, fiscal 20223
  • IndustryBiological Products, (No Diagnostic Substances)2
  • HeadquartersStevenage, United Kingdom2
  • Incorporated inUnited Kingdom4
  • Business addressSycamore House, Gunnels Wood Road, Stevenage, Hertfordshire, X0 Sg1 2Bp4
  • Filer categoryNon-accelerated filer, Emerging growth company4
  • Legal formPublic Limited Company2
  • LEI21380046L1D1Q6QJPH292
  • StatusInactive2
  • LEI statusRetired2
  • Registered addressSYCAMORE HOUSE, SG1 2BP Stevenage, United Kingdom2
  • Registered withCompanies House, 125464792

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-169.7%Return on equity3
-$85.2MFree cash flow3

Financial statements

Operating income563-$98.4M in 2022+140% since 2018
-$150.0M-$100.0M-$50.0M02018: -$41.0M-$41.0M20182019: -$63.6M-$63.6M2019+55%2020: -$102.4M-$102.4M2020+61%2021: -$142.4M-$142.4M2021+39%2022: -$98.4M-$98.4M2022−31%
Net income563-$89.0M in 2022+167% since 2018
-$150.0M-$100.0M-$50.0M02018: -$33.3M-$33.3M20182019: -$53.9M-$53.9M2019+62%2020: -$96.3M-$96.3M2020+79%2021: -$140.4M-$140.4M2021+46%2022: -$89.0M-$89.0M2022−37%
Fiscal year201720182019202020212022
Research and development$34.2M5$47.0M6$76.1M3$95.4M3$66.2M3
Operating expenses$142.4M3$98.4M3
Operating income-$41.0M5-$63.6M6-$102.4M3-$142.4M3-$98.4M3
Income before tax-$140.0M3-$88.6M3
Income tax$27.0K5$141.0K6$129.0K3$342.0K3$368.0K3
Net income-$33.3M5-$53.9M6-$96.3M3-$140.4M3-$89.0M3
Earnings per share-$6.813-$3.933-$1.503
Earnings per share (diluted)-$6.813-$3.933-$1.503
Shares (weighted, basic)35.7M shares359.3M shares3
Shares (weighted, diluted)35.7M shares359.3M shares3

Compare Freeline Therapeutics Holdings plc with another company

Corporate structure

Freeline Therapeutics Holdings plc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Freeline Therapeutics Holdings plc

  • Freeline Therapeutics Holdings plc Stevenage, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Freeline Therapeutics Holdings plc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.0M3 Dec 31, 2022$16.7M3 Dec 31, 2021−16.2%
Accumulated depreciation$5.0M3 Dec 31, 2022$6.8M3 Dec 31, 2021−26.6%
Property and equipment, net$9.0M3 Dec 31, 2022$9.9M3 Dec 31, 2021−9.1%
Operating-lease assets (leased space)$6.0M3 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$47.3M3 Dec 31, 2022$117.7M3 Dec 31, 2021−59.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$8.0K3 Dec 31, 2021$23.0K6 Dec 31, 2020−65.2%

Former names

  • Freeline Therapeutics Holdings LtdMay 7, 2020 to Jul 10, 20204

Timeline

  1. Apr 3, 2020Founded Freeline Therapeutics Holdings plc is founded2

Filings

77 filings to the SEC since October 2021: 2 annual reports, 17 large holders, 58 other. The latest 20:

  1. Mar 1, 202415-12G EDGAR
  2. Feb 23, 2024EFFECT EDGAR
  3. Feb 22, 2024S-8 POS EDGAR
  4. Feb 22, 2024S-8 POS EDGAR
  5. Feb 22, 2024S-8 POS EDGAR
  6. Feb 22, 2024S-8 POS EDGAR
  7. Feb 22, 2024POS AM EDGAR
  8. Feb 22, 2024SC 13D/A EDGAR
  9. Feb 20, 2024SC 13E3/A EDGAR
  10. Feb 20, 20246-K EDGAR
  11. Feb 14, 2024SC 13G/A EDGAR
  12. Feb 12, 2024SC 13G/A EDGAR
  13. Feb 12, 20246-K EDGAR
  14. Jan 31, 2024SC 13G/A FREELINE THERAPEUTICS HOLDINGS PLC EDGAR
  15. Jan 18, 20246-K EDGAR
  16. Jan 17, 2024SC 13E3/A EDGAR
  17. Dec 8, 2023SC 13E3 EDGAR
  18. Dec 1, 20236-K EDGAR
  19. Nov 24, 2023SC 13D/A EDGAR
  20. Nov 22, 20236-K EDGAR

The 77 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Freeline Therapeutics Holdings plc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARFreeline Therapeutics Holdings plc1
  • CIK0001810031
  • Filer statusNon-accelerated filer<br>emerging growth company1
  • Incorporated inUnited Kingdom1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressSycamore House, Gunnels Wood Road, Stevenage, Hertfordshire, X0 SG1 2BP1
  • Phone44 (0)1438 9068701
  • Shares outstanding65,113,575 as of Dec 31, 20223
  • On EDGAR sinceMay 7, 20201
  • Filings135 in all: 6-K (59), SC 13G/A (11), SC 13G (7), CORRESP (5), UPLOAD (5), 424B5 (4), DRS/A (4), EFFECT (4)1
    All 32 form types

    S-8 (4), S-8 POS (4), 20-F (3), SC 13D/A (3), DRSLTR (2), SC 13E3/A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1/A (1), F-1MEF (1), F-3 (1), F-6 (1), F-6 POS (1), F-6/A (1), F-6EF (1), FWP (1), POS AM (1), SC 13D (1), SC 13E3 (1)

  • Latest filingsAnnual report (20-F) Apr 4, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13